PrimeRFP SCOUT · Federal Contract Recompete Brief

W911SR22D0009Complete advanced development of the monoclonal — Ology Bioservices, Inc

Ology Bioservices, Inc holds $17.4M across 7 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 3 related awards in the incumbent pipeline. Set-aside status: NONE.

W6qk Acc-Apg
Awarding office
Ology Bioservices, Inc
Recipient
Estimated value
AN42
PSC
NONE
Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Ology Bioservices, Inc — $90

Contract facts

NONE
Contract numberW911SR22D0009
Also listed asW911SR-22-D-0009
AgencyW6qk Acc-Apg
Awarding officeW6qk Acc-Apg
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentOlogy Bioservices, Inc
UEIGC2RFAZK8G64
PSCAN42
Related solicitationW911SR22R0040

THIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO BOTULINUM TOXIN. is a federal NONE award for W6qk Acc-Apg held by Ology Bioservices, Inc. Estimated value —. Related solicitation W911SR22R0040.

THIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO BOTULINUM TOXIN.

Incumbent footprint

Public record

Ology Bioservices, Inc$17.4M obligated across 7 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($17.4M) · all agencies
Department of Defense (DOD)$11.6M · 67%Department of Health and Human Services (HHS)$5.8M · 33%

Related awards

Same incumbent
W911SR23F0057
DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEV…
$67.6M
Jan 5, 2028
W911SR22F0073
DS PROCESS CHARACTERIZATION
$10.8M
Jan 5, 2028
W911SR22F0014
CLINICAL DEVELOPMENT PHASE 2 STUDY
$107.9M
Feb 29, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract W911SR22D0009?

W911SR22D0009 (Complete advanced development of the monoclonal) is a W6qk Acc-Apg award with an estimated value of —, currently held by Ology Bioservices, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W911SR-22-D-0009?

W911SR-22-D-0009 is the dashed form of PIID W911SR22D0009 (Complete advanced development of the monoclonal), held by Ology Bioservices, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W911SR22D0009?

W6qk Acc-Apg awarded W911SR22D0009 to Ology Bioservices, Inc.

Who is the incumbent on W911SR22D0009?

Ology Bioservices, Inc is the incumbent with $17.4M across 7 related awards in SCOUT’s public footprint.

When does Ology Bioservices, Inc’s W911SR22D0009 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on W911SR22D0009 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W911SR22D0009